Here’s a concise update on Wegovy (semaglutide) current events:
FDA approval of Wegovy as a pill: In late 2025, news outlets reported that the FDA approved an oral tablet form of Wegovy, marking a first for this line of GLP-1 therapies and potentially broadening access beyond injections [BBC: Wegovy pill approved by US FDA for weight loss]. This shift could impact Novo Nordisk’s sales strategy and competition in the weight-loss drug market [BBC: Wegovy pill approval snippet].[1]
Pricing and affordability actions: There have been notable price-related moves around Wegovy in 2025, including efforts to reduce out-of-pocket costs and make the drug more affordable for uninsured or underinsured patients in some contexts [ABC News: Wegovy affordability; CBS News: price cuts and related developments]. These actions are part of broader industry pressure on obesity drugs and may influence patient access and insurer coverage.
Additional clinical and market news: Wegovy has continued to generate clinical and strategic headlines, including trial outcomes related to safety or cardiovascular endpoints, and market dynamics around competition from other GLP-1 therapies (e.g., potential rivals from Eli Lilly) as the weight-management drug market expands [CNBC: Wegovy heart-disease trial; CNBC: Wegovy market context]. There were also developments around related indications or approvals, such as potential expansions to treat other conditions (e.g., liver disease, per some outlets in 2025) [CNBC: Wegovy liver disease trial].
If you’d like, I can pull lighter-weight, current-source summaries for specific aspects (FDA status, pricing changes, or key trial results) or provide a quick timeline of major Wegovy milestones in 2024–2025. Also tell me if you want local U.S. updates only or global coverage.
Citations:
/PRNewswire/ -- Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved the new drug application (NDA) for Wegovy™...
www.prnewswire.comMr. Trump announced a deal with two pharmaceutical companies to reduce the cost of popular medicines, including Wegovy and Zepbound. CBS News New York's Gwen Baumgardner has the details. Novo Nordisk said it will stop selling Wegovy on Hims & Hers, claiming the telehealth company sold knockoff versions of the weight-loss drug.
www.cbsnews.comNews details
www.novonordisk-us.comLearn about Wegovy® (semaglutide) injection 2.4 mg, 7.2 mg or tablets 25 mg for adults with obesity or overweight and see how it supports weight loss with guidance, dosing information, and savings resources to help you get started. Read important safety and prescribing info, including boxed warning.
www.wegovy.comDrugmaker Novo Nordisk says it will make the popular weight GLP-1 weight loss medication Wegovy more affordable for those without insurance coverage, dropping the price to $349 a month.
abcnews.go.comNovo Nordisk has been swept up in uncertainty around U.S. tariffs and Washington's push to get firms to lower drug prices and move manufacturing stateside.
www.cnbc.comWegovy becomes first pill of its kind to be approved, shifting weight-loss drugs beyond injections.
www.bbc.comThe maker of Ozempic is cutting the price of the drug nearly in half for some patients. Novo Nordisk had already cut the price of Wegovy, a medication with the same active ingredient that's approved for weight loss. Dr. Celine Gounder has more on the emerging price competition over the drugs. Drugmaker Eli Lilly said Thursday that things are looking good for their latest weight loss drug that would be available as a pill. Dr. Jon LaPook reports. Novo Nordisk said it will stop selling Wegovy on...
www.cbsnews.com